ABSI
Absci Corporation
There isn't enough reported data to score ABSI yet.
LLY
Eli Lilly and Company
LLY's fundamentals are strong: revenue grew 46% and it turned 23% of its revenue into free cash flow. At 46x earnings, it's trading in line with its usual 48x. Analysts expect that strong growth to continue.
ABSI Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Weak | |
| Weak | |
| Unavailable |
ABSI's revenue, profitability and cash flow are currently under pressure. There isn't enough data to rate its balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
ABSI PE Valuation
ABSI has no meaningful PE right now: it lost money over the past year.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
ABSI Forward outlook
There aren't enough analyst estimates for ABSI to show an outlook.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
Analysts expect strong earnings and revenue growth for LLY, with profitability improving.
ABSI Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | -$0.78 | +$0.13 |
| Q2 2026 | -$0.79 | +$0.16 |
| Q1 2026 | -$0.82 | +$0.11 |
| Q4 2025 | -$0.84 | +$0.10 |
| Q3 2025 | -$0.91 | +$0.02 |
| Q2 2025 | -$0.95 | -$0.02 |
| Q1 2025 | -$0.93 | +$0.23 |
| Q4 2024 | -$0.94 | +$0.26 |
ABSI is still losing money, but far less than before: $0.78 per share over the past year, against $2.89 at its worst in late 2021.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.82 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY has the edge over ABSI on earnings quality, reporting a profit while its opponent remains loss making.
ABSI Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $304K | -20% |
| Q2 2026 | $318K | -46% |
| Q1 2026 | $215K | -82% |
| Q4 2025 | $650K | -2.3% |
| Q3 2025 | $378K | -78% |
| Q2 2025 | $593K | -53% |
| Q1 2025 | $1.2M | +31% |
| Q4 2024 | $665K | +97% |
ABSI's revenue has slid since its 2023 peak: $304,000 last quarter, down 20% from the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -11511% | -3534 points |
| Q2 2026 | -10742% | -5448 points |
| Q1 2026 | -14347% | -11995 points |
| Q4 2025 | -4776% | -298 points |
| Q3 2025 | -7977% | -6279 points |
| Q2 2025 | -5294% | -3190 points |
| Q1 2025 | -2352% | +265 points |
| Q4 2024 | -4477% | +2842 points |
ABSI's operating margin was −11511% last quarter, down 3534 points from the same quarter a year ago, near the bottom of its range since 2020.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over ABSI on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over ABSI on profitability, with a higher operating margin.
ABSI Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$29.5M | -$3.5M |
| Q2 2026 | -$27.6M | -$10.5M |
| Q1 2026 | -$26.3M | -$4.5M |
| Q4 2025 | -$29.1M | -$12.1M |
| Q3 2025 | -$26M | -$5.2M |
| Q2 2025 | -$17.1M | +$80K |
| Q1 2025 | -$21.9M | -$4M |
| Q4 2024 | -$17M | -$2M |
ABSI has burned cash in almost every quarter: −$112M over the past year, against −$82M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over ABSI on cash generation, producing positive trailing cash flow while its opponent burns cash.
ABSI Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +9.1% | +14.3M shares |
| 1 year | +19% | +28M shares |
| 3 years | +86% | +79.6M shares |
| 5 years | +874% | +154M shares |
| Available history | +90% | +81.4M shares |
ABSI has 172M diluted shares, up 19% from a year ago.
| Quarter | Spent |
|---|---|
| Q1 2021 | — |
| Q4 2020 | — |
| Q3 2020 | — |
| Q2 2020 | — |
| Q1 2020 | — |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over ABSI on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
ABSI Net Leverage
ABSI's operating earnings (EBITDA) were negative over the past year, so its debt can't be measured against them.
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
ABSI Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 52.8 | Neutral |
| Stochastic | 52.6 | Neutral |
ABSI's weekly RSI is 53 (neutral) and its Stochastic is 53 (neutral).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
ABSI PE vs Healthcare Sector
ABSI has no meaningful PE right now: it lost money over the past year.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
ABSI Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $9.85 | 7.3% below |
| 20 week MA | $9.39 | 2.8% below |
| 50 week MA | $6.24 | 46% above |
| 100 week MA | $4.70 | 94% above |
| 200 week MA | $3.87 | 136% above |
ABSI has pulled back, but its long-term trend is still up: it's below its 8- and 20-week averages, but 136% above its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over ABSI on trend strength, trading above more of its moving averages.
ABSI Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2021 | $22.9 | $8.67 | -62% |
| 2022 | $8.67 | $2.17 | -75% |
| 2023 | $2.17 | $4.20 | +94% |
| 2024 | $4.20 | $2.77 | -34% |
| 2025 | $2.77 | $3.57 | +29% |
| 2026 YTD | $3.57 | $9.13 | +156% |
ABSI has the edge over LLY on returns for 2026, with the stronger performance.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has finished every year since 2020 higher, and it's up 32% so far in 2026.